Gene expression profiling and genetic markers in glioblastoma survival

Cancer Research

Volumn 65, Issue 10, 2005, Pages 4051-4058

  Rich, Jeremy N ^a   Hans, Christopher ^a   Jones, Beatrix ^a,b   Iversen, Edwin S ^a   McLendon, Roger E ^a   Rasheed, B K Ahmed ^a   Dobra, Adrian ^a   Dressman, Holly K ^a   Bigner, Darell D ^a   Nevins, Joseph R ^a   West, Mike ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MASSEY UNIVERSITY   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; MUTANT PROTEIN; OSTEONECTIN; PHOSPHATASE; PROTEIN; PROTEIN DOUBLECORTEX; PROTEIN P16INK4A; PROTEIN P53; SEMAPHORIN; SEMAPHORIN 3B; TENSIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER SURVIVAL; CELL MIGRATION; CLINICAL ARTICLE; DNA MICROARRAY; DOUBLECORTEX GENE; FEMALE; GENE; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ANALYSIS; GENETIC MARKER; GLIOBLASTOMA; HUMAN; MALE; MULTIPLE REGRESSION; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; REGRESSION ANALYSIS; SPARC GENE; STATISTICAL ANALYSIS; VALIDATION PROCESS;

AGED; BRAIN NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENE EXPRESSION PROFILING; GENETIC MARKERS; GLIOBLASTOMA; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MEMBRANE GLYCOPROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEUROPEPTIDES; OSTEONECTIN; PHOSPHORIC MONOESTER HYDROLASES; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; SEMAPHORINS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 20144376240     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3936     Document Type: Article

References (50)

1. Legler JM, Ries LA, Smith MA, et al. Brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst 1999;91: 1382-90.
2. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
3. Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 2003;21:1624-36.
4. Kleihues P, Cavenee WK, editors. Pathology and genetics of tumours of the nervous system. Lyon: IARC Press; 2000. p. 3-70.
5. Lamborn KR, Chang SM, Prados MD. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro-oncol 2004;6: 227-35.
6. Sawaya R. Extent of resection in malignant gliomas: a critical summary. J Neurooncol 1999;42:303-5.
7. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359: 1011-8.
8. Rich JN, Bigner DD. Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 2004;3:430-46.
9. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neurooncol 1999;1:44-51.
10. Smith JS, Tachibana I, Passe SM, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 2001;93:1246-56.
11. Nutt CL, Mani DR, Betensky RA, et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 2003;63:1602-7.
12. Godard S, Getz G, Delorenzi M, et al. Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res 2003;63:6613-25.
13. Freije WA, Castro-Vargas FE, Fang Z, et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res 2004;64:6503-10.
14. Mischel PS, Cloughesy TF, Nelson SF. DNA-microarray analysis of brain cancer: molecular classification for therapy. Nat Rev Neurosci 2004;5:782-92.
15. Reardon DA, Akabani G, Coleman RE, et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 2002;20: 1389-97.
16. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003;31:e15.
17. Bioconductor: Open source software for bioinformatics. http://www.bioconductor.org.
18. Hans C, Dobra A, West M. Shotgun stochastic search in regression, in Discussion Paper, ISDS, Durham: Duke University: 2004.
19. Pittman J, Huang E, Dressman H, et al. Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc Natl Acad Sci U S A 2004;101:8431-6.
20. Huang E, Cheng SH, Dressman H, et al. Gene expression predictors of breast cancer outcomes. Lancet 2003; 361:1590-6.
21. Pittman J, Huang E, Nevins J, Wang Q, West M. Bayesian analysis of binary prediction tree models for retrospectively sampled outcomes. Biostatistics 2004;5: 587-601.
22. Nozaki M, Tada M, Kobayashi H, et al. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression. Neuro-oncol 1999;1: 124-37.
23. Dobra A, Jones B, Hans C, Nevins JR, West M. Sparse graphical models for exploring gene expression data. J Multivariate Analysis 2004;90:196-212.
24. Jones B, Dobra A, Carvalho C, Hans C, Carter C, West M. Experiments in stochastic computation for high-dimensional graphical models. Statistical Science. In press 2005.
25. Roth JG, Elvidge AR. Glioblastoma multiforme: a clinical study. J Neurosurg 1962;17:736-50.
26. Silbergeld DL, Rostomily RC, Alvord EC Jr. The cause of death in patients with glioblastoma is multifactorial: clinical factors and autopsy findings in 117 cases of supratentorial glioblastoma in adults. J Neurooncol 1991;10:179-85.
27. Bradshaw AD, Sage EH. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest 2001;107: 1049-54.
28. Termine JD, Kleinman HK, Whitson SW, Conn KM, McGarvey ML, Martin GR. Osteonectin, a bone-specific protein linking mineral to collagen. Cell 1981; 26:99-105.
29. Porter PL, Sage EH, Lane TF, Funk SE, Gown AM. Distribution of SPARC in normal and neoplastic human tissue. J Histochem Cytochem 1995;43:791-800.
30. Rempel SA, Golembieski WA, Ge S, et al. SPARC: a signal of astrocytic neoplastic transformation and reactive response in human primary and xenograft gliomas. J Neuropathol Exp Neurol 1998;57:1112-21.
31. Rempel SA, Ge S, Gutierrez JA. SPARC: a potential diagnostic marker of invasive meningiomas. Clin Cancer Res 1999;5:237-41.
32. Thomas R, True LD, Bassuk JA, Lange PH, Vessella RL. Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res 2000;6:1140-9.
33. Bellahcene A, Castronovo V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol 1995;146: 95-100.
34. Lal A, Lash AE, Altschul SF, et al. A public database for gene expression in human cancers. Cancer Res 1999;59: 5403-7.
35. Golembieski WA, Ge S, Nelson K, Mikkelsen T, Rempel SA. Increased SPARC expression promotes U87 glioblastoma invasion in vitro. Int J Dev Neurosci 1999;17:463-72.
36. Vajkoczy P, Menger MD, Goldbrunner R, et al. Targeting angiogenesis inhibits tumor infiltration and expression of the pro-invasive protein SPAKC. Int J Cancer 2000;87:261-8.
37. Rich JN, Shi Q, Hjelmeland M, et al. Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. J Biol Chem 2003;278: 15951-7.
38. Schultz C, Lemke N, Ge S, Golembieski WA, Rempel SA. Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo. Cancer Res 2002;62:6270-7.
39. Shi Q, Bao S, Maxwell JA, et al. Secreted protein acidic, rich in cysteine (SPARC) mediates cellular survival of gliomas through AKT activation. J Biol Chem 2004;279:52200-9.
40. Gleeson JG, Allen KM, Fox JW, et al. Doublecortin, a brain-specific gene mutated in human X-linked lissencephaly and double cortex syndrome, encodes a putative signaling protein. Cell 1998;92:63-72.
41. Francis F, Koulakoff A, Boucher D, et al. Doublecortin is a developmentally regulated, microtubule-associated protein expressed in migrating and differentiating neurons. Neuron 1999;23:247-56.
42. Tanaka T, Serneo FF, Tseng HC, Kulkarni AB, Tsai LH, Gleeson JG. Cdk5 phosphorylation of doublecortin ser297 regulates its effect on neuronal migration. Neuron 2004;41:215-27.
43. Schaar BT, Kinoshita K, McConnell SK. Doublecortin microtubule affinity is regulated by a balance of kinase and phosphatase activity at the leading edge of migrating neurons. Neuron 2004;41:203-13.
44. Li L, He F, Litofsky NS, Recht LD, Ross AH. Profiling of genes expressed by PTEN haploinsufficient neural precursor cells. Mol Cell Neurosci 2003; 24:1051-61.
45. Cheung M, Abu-Elmagd M, Clevers H, Scotting PJ. Roles of Sox4 in central nervous system development. Brain Res Mol Brain Res 2000;79:180-91.
46. Schilham MW, Oosterwegel MA, Moerer P, et al. Defects in cardiac outflow tract formation and pro-B-lymphocyte expansion in mice lacking Sox-4. Nature 1996;380:711-4.
47. Lee CJ, Appleby VJ, Orme AT, Chan WI, Scotting PJ. Differential expression of SOX4 and SOX11 in medulloblastoma. J Neurooncol 2002;57:201-14.
48. Takahashi T, Nakamura F, Jin Z, Kalb RG, Strittmatter SM. Semaphorins A and E act as antagonists of neuropilin-1 and agonists of neuropilin-2 receptors. Nat Neurosci 1998;1:487-93.
49. Lerman MI, Minna JD. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Cancer Res 2000;60: 6116-33.
50. Ochi K, Mori T, Toyama Y, Nakamura Y, Arakawa H. Identification of semaphorin3B as a direct target of p53. Neoplasia 2002;4:82-7.